Sales of Emerging Novel Pain Therapies Will Represent More than One-Fifth of the...

Sales of Emerging Novel Pain Therapies Will Represent More than One-Fifth of
the Total Pain Drug Market by 2023
Total Drug Market for Pain Will Reach More Than $47 Billion in 2023, According
to a New Report from Decision Resources

WALTHAM, Mass., Aug. 5 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and healthcare
issues, finds that although strong opioids and non-steroidal anti-inflammatory
drugs (NSAIDs) will continue to dominate the pain market over the next 15
years, novel drug classes will claim over one-fifth of total market share by
2023.
The new special Pharmacor report entitled Novel Approaches to Pain finds
that the overall pain market will reach more than $47 billion in 2023 in the
United States, France, Germany, Italy, Spain, United Kingdom and Japan. From
2008 to 2013, reformulations and emerging therapies in existing drug classes
will be the primary drivers of market growth while from 2013 to 2023, growth
will result predominantly from the launch of innovative agents representing
entirely new drug classes. Therapies representing novel drug classes will
expand the pain market by adding to the eight major analgesic drug classes,
creating as many as 18 drug classes by 2023, according to the report.
The most successful reformulations and emerging therapies in existing drug
classes will be abuse- and dependence-resistant strong opioid formulations,
including King Pharmaceuticals/Pain Therapeutics' Remoxy; as well as safer and
more tolerable NSAID formulations such as NicOx's naproxcinod and
AstraZeneca/POZEN's naproxen/esomeprazole combination; Johnson & Johnson's new
dual-acting weak opioid tapentadol; and longer lasting antimigraine
formulations such as GlaxoSmithKline's Treximet.
Of the novel drug classes expected to launch for pain through 2023, the
calcitonin gene-related peptide receptor antagonists, growth factor
modulators, and subtype-selective ion channel modulators will have the most
growth impact owing to their potential efficacy advantages over existing drug
classes. All three of these novel drug classes are forecast to attain
blockbuster peak-year sales.
"The most commercially promising drugs with novel mechanisms of action are
being developed for the treatment of chronic pain that is either inflammatory
or neuropathic in origin," said Natalie Taylor, Ph.D., analyst at Decision
Resources. "Current therapies for inflammatory pain, such as the NSAID drug
class, are plagued by safety concerns when administered over the long-term,
while current therapies for neuropathic pain, such as antidepressants and
anti-epileptics, are associated with inconsistent efficacy."
About Decision Resources
Decision Resources (http://www.decisionresources.com) is a world leader in
market research publications, advisory services, and consulting designed to
help clients shape strategy, allocate resources, and master their chosen
markets.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Elizabeth Marshall
Decision Resources, Inc.
781-296-2563
emarshall@dresources.com

SOURCE Decision Resources, Inc.

Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com